Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 43
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
2.
Clin Infect Dis ; 73(11): e4064-e4072, 2021 12 06.
Artículo en Inglés | MEDLINE | ID: mdl-32556143

RESUMEN

BACKGROUND: Data from nonrandomized studies have suggested that hydroxychloroquine could be an effective therapeutic agent against coronavirus disease 2019 (COVID-19). METHODS: We conducted an observational, retrospective cohort study involving hospitalized adult patients with confirmed, mild to severe COVID-19 in a French university hospital. Patients who received hydroxychloroquine (200 mg 3 times daily dosage for 10 days) on a compassionate basis in addition to standard of care (SOC) were compared with patients without contraindications to hydroxychloroquine who received SOC alone. A propensity score-weighted analysis was performed to control for confounders: age, sex, time between symptom onset and admission ≤ 7 days, Charlson comorbidity index, medical history of arterial hypertension, obesity, National Early Warning Score 2 (NEWS2) score at admission, and pneumonia severity. The primary endpoint was time to unfavorable outcome, defined as: death, admission to an intensive care unit, or decision to withdraw or withhold life-sustaining treatments, whichever came first. RESULTS: Data from 89 patients with laboratory-confirmed COVID-19 were analyzed, 84 of whom were considered in the primary analysis; 38 patients treated with hydroxychloroquine and 46 patients treated with SOC alone. At admission, the mean age of patients was 66 years, the median Charlson comorbidity index was 3, and the median NEWS2 severity score was 3. After propensity score weighting, treatment with hydroxychloroquine was not associated with a significantly reduced risk of unfavorable outcome (hazard ratio, 0.90 [95% confidence interval, .38-2.1], P = .81). Overall survival was not significantly different between the 2 groups (hazard ratio, 0.89 [0.23; 3.47], P = 1). CONCLUSION: In hospitalized adults with COVID-19, no significant reduction of the risk of unfavorable outcomes was observed with hydroxychloroquine in comparison to SOC. Unmeasured confounders may have persisted however, despite careful propensity-weighted analysis and the study might be underpowered. Ongoing controlled trials in patients with varying degrees of initial severity on a larger scale will help determine whether there is a place for hydroxychloroquine in the treatment of COVID-19. In hospitalized adults with COVID-19, no significant reduction of the risk of unfavorable outcomes was observed with hydroxychloroquine in comparison to SOC.


Asunto(s)
Tratamiento Farmacológico de COVID-19 , Hidroxicloroquina , Adulto , Anciano , Ensayos de Uso Compasivo , Hospitales Universitarios , Humanos , Hidroxicloroquina/uso terapéutico , Estudios Retrospectivos , SARS-CoV-2 , Resultado del Tratamiento
3.
Sex Transm Dis ; 48(11): e163-e164, 2021 11 01.
Artículo en Inglés | MEDLINE | ID: mdl-34110731

RESUMEN

ABSTRACT: We present a case of persistent Mycoplasma genitalium urethritis with documented macrolide and fluoroquinolone resistance, and we describe the A2062T mutation in the 23S rRNA gene, possibly associated with pristinamycin resistance. After several treatment failures and loss of the A2062T mutation, M. genitalium urethritis was finally cured by a sequential antibiotic treatment including minocycline.


Asunto(s)
Infecciones por Mycoplasma , Mycoplasma genitalium , Uretritis , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Farmacorresistencia Bacteriana , Humanos , Macrólidos , Infecciones por Mycoplasma/tratamiento farmacológico , Mycoplasma genitalium/genética , Pristinamicina , Uretritis/tratamiento farmacológico
4.
Clin Infect Dis ; 68(12): 2060-2066, 2019 05 30.
Artículo en Inglés | MEDLINE | ID: mdl-30239603

RESUMEN

BACKGROUND: There is no precise idea whether patients with chronic symptoms attributed to Lyme borreliosis (LB) have LB or another disease. METHODS: We evaluated patients consulting for a presumed LB with a holistic approach including presumptive treatment. We included symptomatic patients consulting for presumed LB. They were classified as confirmed LB when they met four criteria, and possible LB if three with a positive clinical response to presumptive treatment. RESULTS: Amongst the 301 patients, 275 (91%) were exposed to tick bites, and 165 (54%) were bitten by a tick. At presentation, 151 patients (50.1%) had already been treated with a median of one (1-22) course of antimicrobials, during 34 (28-730) days. Median number of symptoms was three (1-12) with a median duration of 16 (1-68) months. Median number of signs was zero (0-2). ELISA was positive in 84/295 (28.4%) for IgM and 86/295 (29.1%) for IgG, and immunoblot was positive in 21/191 (10.9%) for IgM and 50/191 (26.1 %) for IgG. Presumptive treatment after presentation failed in 46/88 patients (52%). Diagnosis of LB was confirmed in 29 patients (9.6%), and possible in 9 (2.9%). Of the 243 patients with non-LB diagnosis, diseases were psychological, musculoskeletal, neurological or other origin in 76 (31.2%), 48 (19.7%), 37 (15.2%) and 82 (33.7%) patients respectively. Patients with other diseases were significantly younger, having more symptoms, longest duration of symptoms, less clinical signs and less frequent LB positive serologies. CONCLUSIONS: Overdiagnosis and overtreatment of LB is worsening. Health authorities should investigate this phenomenon.


Asunto(s)
Salud Holística , Enfermedad de Lyme/epidemiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Anticuerpos Antibacterianos/farmacología , Anticuerpos Antibacterianos/uso terapéutico , Borrelia burgdorferi , Niño , Manejo de la Enfermedad , Femenino , Humanos , Enfermedad de Lyme/diagnóstico , Enfermedad de Lyme/tratamiento farmacológico , Enfermedad de Lyme/microbiología , Masculino , Persona de Mediana Edad , Adulto Joven
8.
Rev Prat ; 68(8): 881-885, 2018 Oct.
Artículo en Francés | MEDLINE | ID: mdl-30869456

RESUMEN

Syphilis : what's new ? Syphilis is a sexually transmitted disease caused by Treponema pallidum. It is strongly resurgent since the end of the 1990s especially in the MSM community. The diagnosis is serological, sometimes confirmed by the direct examination of a mucocutaneous lesion. Neurological and ophthalmological localizations may be early and involve functional prognosis. Treatment normally relies on intramuscular benzathine penicillin or oral doxycycline. The effectiveness of the treatment is judged on the decrease of the quantitative VDRL.


Syphilis : quoi de nouveau ? La syphilis est une infection sexuellement transmissible (IST) due à une bactérie, Treponema pallidum. Elle est en forte recrudescence depuis la fin des années 1990, notamment dans la communauté homosexuelle. Le diagnostic est sérologique parfois confirmé par l'examen direct d'une lésion cutanéo-muqueuse. Les localisations neurologiques et ophtalmologiques peuvent être précoces et mettre en jeu le pronostic fonctionnel. Le traitement repose normalement sur la benzathine pénicilline retard par voie intramusculaire ou la doxycycline per os. L'efficacité du traitement se juge sur la décroissance du VDRL quantitatif.


Asunto(s)
Minorías Sexuales y de Género , Sífilis , Homosexualidad Masculina , Humanos , Masculino , Penicilina G Benzatina , Sífilis/tratamiento farmacológico , Sífilis/epidemiología , Sífilis/terapia , Treponema pallidum
10.
J Am Acad Dermatol ; 73(5): 809-20, 2015 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-26365596

RESUMEN

BACKGROUND: Neutrophilic dermatoses refer to a group of cutaneous inflammatory disorders characterized by neutrophilic infiltration of the skin. Neutrophilic dermatoses have been reported in association with various conditions including autoimmune diseases, inflammatory bowel diseases, and neoplasia. In the later condition, myeloproliferative disorders and monoclonal gammopathy (monoclonal immunoglobulin [MIg]) are the most frequent. Only few data are available in case of neutrophilic dermatoses associated with MIg regarding the pathophysiology and the clinical outcome. OBJECTIVE: We sought to gain further insight into clinical and biological aspects of neutrophilic dermatoses associated with MIg. METHODS: We report a retrospective series of 26 patients with neutrophilic dermatoses associated with MIg focusing on clinical and biological aspects, with a study of a large panel of cytokines, chemokines, and adhesion molecules. RESULTS: This study reveals an association between MIg IgA isotype and neutrophilic dermatoses, and a specific inflammatory pattern including elevated interleukin 6, vascular endothelial growth factor, monocyte chemotactic protein-1, epidermal growth factor, and intercellular adhesion molecule-1. LIMITATIONS: This is a retrospective study from a single institution with a limited number of participants. CONCLUSION: Our data highlight a strong association between IgA isotype and neutrophilic dermatoses, and the existence of a specific inflammatory profile involving several molecules.


Asunto(s)
Inmunoglobulina A/inmunología , Isotipos de Inmunoglobulinas/inmunología , Paraproteinemias/complicaciones , Paraproteinemias/inmunología , Enfermedades de la Piel/complicaciones , Enfermedades de la Piel/inmunología , Adulto , Anciano , Anciano de 80 o más Años , Moléculas de Adhesión Celular/sangre , Quimiocinas/sangre , Citocinas/sangre , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neutrófilos , Paraproteinemias/diagnóstico , Estudios Retrospectivos , Enfermedades de la Piel/diagnóstico
11.
Rev Prat ; 65(4): 497-501, 2015 Apr.
Artículo en Francés | MEDLINE | ID: mdl-26058193

RESUMEN

Dermatoses in returning travellers are common. These dermatoses are mainly infectious, the most common being bacterial infections of cosmopolitan origin (cellulitis, pyoderma and abcess). Others dermatoses are environmental diseases such as sunburns, arthropod-related reactions and superficial injuries. The most common tropical skin disease is hookworm-related cutaneous larva migrans but treating physicians may also face patients with localized cutaneous leishmaniasis, tungiasis, or myiasis. Also some systemic infections can be associated with skin manifestations. The most useful treatments in this setting are oral antihistamines, topical steroids, antibiotics effective against bacterial skin infection, booster for tetanus immunization, and rabies vaccination in case of animal exposure.


Asunto(s)
Enfermedades de la Piel/diagnóstico , Enfermedades de la Piel/terapia , Viaje , Humanos
12.
Semin Cutan Med Surg ; 33(3): 116-8, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-25577849

RESUMEN

Pediculosis (capitis, corporis, and pubis) share well-known features: worldwide prevalence (involving millions of people annually); parasites inducing skin lesions directly, and indirectly as a result of itching and hypersensitivity to parasites; and treatment based on good entomological knowledge of the parasite and practical considerations (ie, most available treatments do not act on eggs and should be repeated, depending on the life cycle of the parasites). Infestations are spread most commonly by close contacts. Social stigma and persistent misconceptions complicate the implementation of appropriate management strategies. Head and pubic lice infestations are diagnosed by the visualization of insects or viable nits (eggs). Primary treatments are topical pediculicides (permethrin or malathion), used twice, but emergence of resistance against pediculicides has created the need of alternative treatments including topical or oral ivermectin. Pubic lice are treated the same as head lice, but this finding should prompt evaluation for other sexually transmitted diseases. Body lice infestation should be suspected when symptoms of generalized itching occur in persons who do not change or wash their clothing or bedding regularly; lice may be found in the seams of their clothing.Topically administered permethrin may help to eradicate body lice, but personal hygiene measures are essential for successful treatment. Environmental treatment is also necessary for the eradication of the infestation. Health care personnel who come into contact with this population need to be well informed of the facts in order to disseminate accurate information for diagnosis and management.


Asunto(s)
Infestaciones por Piojos/diagnóstico , Animales , Chrysanthemum cinerariifolium/efectos adversos , Estudios Transversales , Resistencia a Medicamentos , Hexaclorociclohexano/efectos adversos , Hexaclorociclohexano/uso terapéutico , Humanos , Insecticidas/efectos adversos , Insecticidas/uso terapéutico , Ivermectina/efectos adversos , Ivermectina/uso terapéutico , Infestaciones por Piojos/tratamiento farmacológico , Infestaciones por Piojos/epidemiología , Infestaciones por Piojos/transmisión , Malatión/efectos adversos , Malatión/uso terapéutico , Pediculus/anatomía & histología , Permetrina/uso terapéutico
14.
Am J Trop Med Hyg ; 108(2): 340-345, 2023 02 01.
Artículo en Inglés | MEDLINE | ID: mdl-36535252

RESUMEN

Strongyloidiasis is a frequent and often unrecognized parasitic disease because of the frequently asymptomatic nature and lack of sensitivity of diagnostic tests. Under conditions of immunosuppression (particularly systemic corticosteroid treatment), potentially fatal dissemination may occur. Thus, prevention and early diagnosis are important. Larva currens is a rare and pathognomonic cutaneous sign of strongyloidiasis, but is poorly described because of its unpredictable and fleeting occurrence. We report seven imported cases of larva currens seen in Paris between 1990 and 2020. We illustrate the clinical and biological features of this specific but uncommon sign of strongyloidiasis with clinical pictures. There were three males and four females, aged between 29 and 58 years. There were five migrants from endemic countries, one tourist and one expatriate. Digestive disorders were the main extracutaneous signs. All patients had eosinophilia above 0.5 G/L. All cases were confirmed by stool tests. All were cured with ivermectin. The rapidity and the short duration of the creeping eruption distinguish it from other parasitoses. Ivermectin is a treatment of choice. The key point is to think about preventing disseminated strongyloidiasis before giving corticosteroids not only among migrants but also among expatriates and tourists in endemic countries.


Asunto(s)
Larva Migrans , Strongyloides stercoralis , Estrongiloidiasis , Masculino , Femenino , Humanos , Adulto , Persona de Mediana Edad , Animales , Estrongiloidiasis/diagnóstico , Estrongiloidiasis/tratamiento farmacológico , Estrongiloidiasis/parasitología , Ivermectina/uso terapéutico , Larva Migrans/diagnóstico , Piel , Larva
15.
PLoS Negl Trop Dis ; 17(4): e0011238, 2023 04.
Artículo en Inglés | MEDLINE | ID: mdl-37079647

RESUMEN

INTRODUCTION: Leprosy reactions (LRs) are inflammatory responses observed in 30%-50% of people with leprosy. First-line treatment is glucocorticoids (GCs), often administered at high doses with prolonged courses, resulting in high morbi-mortality. Methotrexate (MTX) is an immunomodulating agent used to treat inflammatory diseases and has an excellent safety profile and worldwide availability. In this study, we describe the efficacy, GCs-sparing effect and safety of MTX in LRs. METHODS: We conducted a retrospective multicentric study in France consisting of leprosy patients receiving MTX for a reversal reaction (RR) and/or erythema nodosum leprosum (ENL) since 2016. The primary endpoint was the rate of good response (GR) defined as the complete disappearance of inflammatory cutaneous or neurological symptoms without recurrence during MTX treatment. The secondary endpoint was the GCs-sparing effect, safety and clinical relapse after MTX discontinuation. RESULTS: Our study included 13 patients with LRs (8 men, 5 women): 6 had ENL and 7 had RR. All patients had had at least one previous course of GCs and 2 previous treatment lines before starting MTX. Overall, 8/13 (61.5%) patients had GR, allowing for GCs-sparing and even GCs withdrawal in 6/11 (54.5%). No severe adverse effects were observed. Relapse after MTX discontinuation was substantial (42%): the median relapse time was 5.5 months (range 3-14) after stopping treatment. CONCLUSION: MTX seems to be an effective alternative treatment in LRs, allowing for GCs-sparing with a good safety profile. Furthermore, early introduction during LRs may lead to a better therapeutic response. However, its efficacy seems to suggest prolonged therapy to prevent recurrence.


Asunto(s)
Eritema Nudoso , Lepra Lepromatosa , Lepra , Masculino , Humanos , Femenino , Metotrexato/uso terapéutico , Estudios Retrospectivos , Eritema Nudoso/tratamiento farmacológico , Eritema Nudoso/complicaciones , Lepra/tratamiento farmacológico , Lepra Lepromatosa/complicaciones , Glucocorticoides , Recurrencia
16.
Lancet Infect Dis ; 23(1): 74-80, 2023 01.
Artículo en Inglés | MEDLINE | ID: mdl-36183707

RESUMEN

BACKGROUND: Monkeypox virus (MPXV) is currently spreading among men who have sex with men, outside of sub-Saharan Africa, and close contact during sex seems to be one of the key pathways of viral transmission in the current outbreak. Our aim was to describe the distribution of MPXV in the human body, as it might play a role in its dissemination through sexual contact. METHODS: The study population in this case series consisted of patients with confirmed MPXV infection attending the Pitié-Salpêtrière Hospital (Paris, France), who had been sampled from multiple anatomical sites, including skin, anus, throat, blood, urine, and semen, at diagnosis and 2 weeks later. We compared the proportion of positive samples and MPXV viral loads (given as PCR cycle thresholds [Ct]) between anatomical sites, and between day 0 (D0) and D14. FINDINGS: Overall, 356 samples were collected between May 20 and June 13, 2022, from 50 men with a median age of 34 years (IQR 29-40). 22 (44%) of the 50 men were classified as HIV-negative on day (D)0, and 22 (44%) were living with HIV. At D0, MPXV detection was more frequent from skin (44 [88%] of 50), anus (30 [71%] of 42), and throat (36 [77%] of 47) than from blood (13 [29%] of 45), urine (nine [22%] of 41), or semen (13 [54%] of 24). Viral loads were significantly higher from skin lesions (Ct 19·8) and anal samples (Ct 20·9) than from throat (Ct 27·2), blood (Ct 32·8), urine (31·1), or semen samples (Ct 27·8). When analysing the 107 samples taken from 24 patients at D14, the proportion of positive samples strongly decreased between D0 and D14 at all sites: skin (four [22%] of 18), anus (two [9%] of 22), throat (none of 21), blood (one [5%] of 21), urine (none of 14), and semen (two [9%] of 11). INTERPRETATION: These data contribute to a better understanding of how the virus might spread between sexual partners over a relatively short period of time. High MPXV viral loads from skin and mucosa, including genital and anal sites, suggest that transmission most likely occurs through direct body contact rather than through the respiratory route or contact with body fluids, which should help to refine the prevention messages delivered to individuals most exposed to the virus. FUNDING: None.


Asunto(s)
Infecciones por VIH , Mpox , Minorías Sexuales y de Género , Masculino , Humanos , Adulto , Monkeypox virus , Mpox/epidemiología , Mpox/diagnóstico , Carga Viral , Homosexualidad Masculina , Infecciones por VIH/epidemiología
17.
Cell Host Microbe ; 31(6): 937-948.e4, 2023 06 14.
Artículo en Inglés | MEDLINE | ID: mdl-37196656

RESUMEN

Mpox virus (MPXV) caused a multi-country outbreak in non-endemic areas in 2022. Following historic success of smallpox vaccination with vaccinia virus (VACV)-based vaccines, the third generation modified vaccinia Ankara (MVA)-based vaccine was used as prophylaxis for MPXV, but its effectiveness remains poorly characterized. Here, we applied two assays to quantify neutralizing antibodies (NAbs) in sera from control, MPXV-infected, or MVA-vaccinated individuals. Various levels of MVA NAbs were detected after infection, historic smallpox, or recent MVA vaccination. MPXV was minimally sensitive to neutralization. However, addition of complement enhanced detection of responsive individuals and NAb levels. Anti-MVA and -MPXV NAbs were observed in 94% and 82% of infected individuals, respectively, and 92% and 56% of MVA vaccinees, respectively. NAb titers were higher in individuals born before 1980, highlighting the impact of historic smallpox vaccination on humoral immunity. Altogether, our results indicate that MPXV neutralization is complement dependent and uncover mechanisms underlying vaccine effectiveness.


Asunto(s)
Mpox , Vacuna contra Viruela , Viruela , Humanos , Viruela/prevención & control , Anticuerpos Antivirales , Virus Vaccinia , Anticuerpos Neutralizantes , Proteínas del Sistema Complemento
18.
Skin Therapy Lett ; 17(3): 1-4, 2012 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-22446818

RESUMEN

Scabies is a common contagious parasitic dermatosis. Transmission of the mite Sarcoptes scabiei var hominis generally occurs by skin-to-skin contact, but with crusted scabies it may also occur through fomites, such as infected clothing or bedding. Diagnosis is usually clinical. A 2010 updated Cochrane review concluded that management of scabies is based on topical scabicides, mainly 5% permethrin. However, oral ivermectin, although not licensed in many countries, may be useful, particularly for patients who cannot tolerate or comply with topical therapy and in institutional scabies epidemics. Patients should also receive detailed information about the infestation to limit further spreading. Cases resulting from close physical or sexual contact, even without symptoms, should be systematically treated. Hygienic measures should be taken after treatment is completed. Patients should be followed to confirm cure, including resolution of itching, which may take up to 4 weeks or longer.


Asunto(s)
Antiparasitarios/uso terapéutico , Insecticidas/uso terapéutico , Ivermectina/uso terapéutico , Permetrina/uso terapéutico , Escabiosis/tratamiento farmacológico , Animales , Antiparasitarios/administración & dosificación , Humanos , Insecticidas/administración & dosificación , Ivermectina/administración & dosificación , Permetrina/administración & dosificación , Escabiosis/prevención & control , Escabiosis/transmisión
19.
Infect Dis Now ; 52(1): 13-17, 2022 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-34547546

RESUMEN

OBJECTIVES: We report the characteristics of Mycoplasmagenitalium (MG) infection in patients from a STI center in Paris. We evaluated outcomes after treatment. METHODS: We included all patients tested for MG, Chlamydiatrachomatis (CT) and Neisseria gonorrhoeae (NG) infection in our center from January 2017 to December 2018, using multiplex PCR on urine specimen, vaginal or rectal swabs. We collected data regarding sex, age, HIV status, PrEP use, sexual behavior, NG and CT co-infection, symptoms and treatment. RESULTS: MG infection prevalence was 7% (397/5586) (95% CI 6.4-7.8). It ranged from 4.6% in patients consulting for routine STI testing (3.9% in women, 5% in men), to 16% in HIV-positive patients and 25% in PrEP users. Among the 397 MG infected patients, 351 (88%) were asymptomatic and 87 (22%) were co-infected with NG or CT. Among the 270 (68%) treated patients, 249 (92%) received azithromycin. Failure rate was 74% in the 103 patients tested post-treatment. Treatment failure tended to be higher with azithromycin single dose than with 5-day azithromycin (88% vs. 70%; P=0.07). Azithromycin and moxifloxacin were used as second-line treatment in 24 and 23 patients, respectively. Post-treatment PCR remained positive in 55% of the 44 tested patients with a better eradication rate with moxifloxacin than with azithromycin (70% vs. 33%; P=0.04). CONCLUSION: MG infection is highly prevalent in PrEP users and HIV-positive patients and is mostly asymptomatic. Management of MG infection should be tailored and adapted to the risk of antibiotic resistance and reinfection.


Asunto(s)
Coinfección , Gonorrea , Infecciones por Mycoplasma , Mycoplasma genitalium , Coinfección/epidemiología , Femenino , Gonorrea/diagnóstico , Gonorrea/tratamiento farmacológico , Gonorrea/epidemiología , Humanos , Masculino , Infecciones por Mycoplasma/diagnóstico , Infecciones por Mycoplasma/tratamiento farmacológico , Infecciones por Mycoplasma/epidemiología , Conducta Sexual
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA